Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 2/20 | 0.42 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.39 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.39 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL30437086 | 0.99 | TSHR (0.43) | TSHRHPGDDRD4ADRA1BADRA2A | |
| Water SCHEMBL22491700 | 0.99 | TSHR (0.43) | TSHRHPGDDRD4ADRA1BADRA2A | |
| Water SCHEMBL21048282 | 0.99 | TSHR (0.43) | TSHRHPGDDRD4ADRA1BADRA2A | |
| SCHEMBL20482712 | 0.79 | ADRA2A (0.49) | TSHRHPGDADRA1BADRA2AADRA1D | |
| SCHEMBL30436776 | 0.79 | ADRA2A (0.49) | TSHRHPGDADRA1BADRA2AADRA1D | |
| SCHEMBL20480080 | 0.79 | ADRA2A (0.49) | TSHRHPGDADRA1BADRA2AADRA1D | |
| SCHEMBL22491774 | 0.77 | ADRA2A (0.47) | TSHRDRD4ADRA1BADRA2AADRA1D | |
| SCHEMBL30436956 | 0.77 | ADRA2A (0.47) | TSHRDRD4ADRA1BADRA2AADRA1D | |
| SCHEMBL22466776 | 0.77 | ADRA2A (0.47) | TSHRDRD4ADRA1BADRA2AADRA1D | |
| SCHEMBL22491683 | 0.76 | ADRA2A (0.45) | TSHRDRD4ADRA1BADRA2AADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240173254-A1 | TASIPIMIDINE FORMULATIONS AND USE THEREOF | ORION CORPORATION (FI) | 2024-05-30 | — | — | US | disclosed |
| US-20240165083-A1 | TASIPIMIDINE FORMULATIONS AND USE THEREOF | ORION CORPORATION (FI) | 2024-05-23 | — | — | US | disclosed |
| CN-117157070-A | Tasipiridine (tasipidine) formulations and uses thereof | 奥赖恩公司 | 2023-12-01 | — | — | CN | disclosed |
| CN-117136045-A | Tasipiridine (tasipidine) formulations and uses thereof | 奥赖恩公司 | 2023-11-28 | — | — | CN | disclosed |
| US-11352346-B2 | Process for the preparation of 2-(5-methoxyisochroman-1-yl)-4,5-dihydro-1H-imidazole and the hydrogensulfate salt thereof | ORION CORPORATION (FI) | 2022-06-07 | — | — | US | disclosed |
| EP-3717476-A1 | PROCESS FOR THE PREPARATION OF 2-(5-METHOXYISOCHROMAN-1 -YL)-4,5-DIHYDRO-1 H-IMIDAZOLE AND THE HYDROGENSULFATE SALT THEREOF | Orion Corporation (FI) | 2020-10-07 | — | — | EP | disclosed |
| US-20200308152-A1 | PROCESS FOR THE PREPARATION OF 2-(5-METHOXYISOCHROMAN-1 -YL)-4,5-DIHYDRO-1 H-IMIDAZOLE AND THE HYDROGENSULFATE SALT THEREOF | ORION CORPORATION (FI) | 2020-10-01 | — | — | US | disclosed |
| WO-2019106238-A1 | PROCESS FOR THE PREPARATION OF 2-(5-METHOXYISOCHROMAN-1 -YL)-4,5-DIHYDRO-1 H-IMIDAZOLE AND THE HYDROGENSULFATE SALT THEREOF | ORION CORPORATION (FI) | 2019-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308152-A1 | PROCESS FOR THE PREPARATION OF 2-(5-METHOXYISOCHROMAN-1 -YL)-4,5-DIHYDRO-1 H-IMIDAZOLE AND THE HYDROGENSULFATE SALT THEREOF | ADRA2A, ADRA2C, ADRB2 | TSHR 576/4885HPGD 897/4885DRD4 922/4885 |
| US-11352346-B2 | Process for the preparation of 2-(5-methoxyisochroman-1-yl)-4,5-dihydro-1H-imidazole and the hydrogensulfate salt thereof | ADRA2A, ADRA2C, ADRB2 | TSHR 627/4885HPGD 873/4885DRD4 808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.